证券代码：688298 证券简称：东方生物 公告编号：2024-039 本次毒品检测分析仪取得欧盟IVDR，可配套公司在欧盟已获证的毒品检测试 剂使用，定性检测人体样本中是否存在药物潜在滥用，本产品适用于专业机构操 作，有利于公司相关检测业务在欧洲市场的拓展。 三、风险提示 上述取证产品的实际销售业绩取决于实际市场检测需求，以及公司实际销售 能力和产品竞争实力，敬请投资者注意二级市场投资风险。 特此公告。 浙江东方基因生物制品股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（简称"东方生物"）与全资子公司美 国衡健生物科技有限公司（简称"美国衡健"）（合称"公司"）近日取得芬太 尼尿液检测试剂（专业/自测）的美国食品药品监督管理局FDA 510(K)许可证及毒 品检测分析仪的欧盟IVDR，相关公告如下： | 产品名称 | 证书 | 证书 | 预期 | 授权 | 持证 | | --- | --- | --- | --- | --- | --- ...

重要内容提示： 证券代码：688298 证券简称：东方生物 公告编号：2024-038 浙江东方基因生物制品股份有限公司 关于以集中竞价交易方式回购公司股份比例达到总股本 3% 暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定"回购股份占上市公司总股本的比例每增加 1%的， 应当在事实发生之日起 3 个交易日内予以披露"，现将公司回购股份进展情况公告 如下： 截至 2024 年 5 月 14 日，公司通过上海证券交易所系统以集中竞价交易方式 回购公司股份累计达到 745.72 万股，占公司总股本 20,160.00 万股的比例为 3.70%， 与上次披露数相比增加 1.49%，回购成交的最低价为 31.31 元/股，最高价为 34.50 元/股，累计支付总金额为 2.5 亿元。 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股 ...

浙江东方基因生物制品股份有限公司 2023 年年度股东大会 证券简称：东方生物 证券代码：688298 浙江东方基因生物制品股份有限公司 2023 年年度股东大会会议资料 2024 年 5 月 22 日 1 浙江东方基因生物制品股份有限公司 2023 年年度股东大会 五、要求发言的股东及股东代表，应在会议登记时说明，如果是书面发言， 应同时提交书面发言材料。在股东大会召开过程中，股东及股东代表临时要求口 2 浙江东方基因生物制品股份有限公司 2023 年年度股东大会会议须知 为维护浙江东方基因生物制品股份有限公司（以下简称"公司"）全体股东 的合法权益，确保股东大会的正常秩序和议事效率，保证股东大会如期、顺利召 开，根据《中华人民共和国公司法》、《中华人民共和国证券法》、《浙江东方 基因生物制品股份有限公司章程》、《浙江东方基因生物制品股份有限公司股东 大会议事规则》等相关规定，特制定本股东大会会议须知。 一、为保证本次股东大会的严肃性和正常秩序，切实维护与会股东（或股东 代表）的合法权益，除出席会议的股东（或股东代表）、公司董事、监事、高级 管理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他人员进 ...

重要内容提示： | 回购方案首次披露日 | 年 月 2024 2 8 | | 日，由实际控制人方剑秋先生、 | | | --- | --- | --- | --- | --- | | | 方炳良先生、方效良先生提议 | | | | | 回购方案实施期限 | 年 月 年 月 2024 2 7 2 | 日—2025 | 6 | 日 | | 预计回购金额 | 万元 25,000 万元~30,000 | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | □用于转换公司可转债 | | | | | | □为维护公司价值及股东权益 | | | | | 累计已回购股数 | 444.644 万股 | | | | | 累计已回购股数占总股本比例 | 2.21% | | | | | 累计已回购金额 | 14999.596 万元 | | | | | 实际回购价格区间 | 31.31 元/股~34.50 元/股 | | | | 一、 回购股份的基本情况 证券代码：688298 证券简称：东方生物 公告编号：2024-037 浙江东方基因生物制品股份有限公司 关于以集中竞价交易方式回购公 ...

证券代码：688298 证券简称：东方生物 公告编号：2024-036 浙江东方基因生物制品股份有限公司 关于以集中竞价交易方式回购公司股份比例达到总股本 1% 暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 回购方案首次披露日 | 2024 月 8 日，由实际控制人方剑秋先生、 | 年 | 2 | | | | | --- | --- | --- | --- | --- | --- | --- | | | 方炳良先生、方效良先生提议 | | | | | | | 回购方案实施期限 | 2024 月 7 日—2025 年 月 | 年 | 2 | 2 | 6 | 日 | | 预计回购金额 | 25,000 万元—30,000 万元人民币 | | | | | | | 回购用途 | □减少注册资本 | | | | | | | | ☑用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 ...

证券代码：688298 证券简称：东方生物 公告编号：2024-034 浙江东方基因生物制品股份有限公司 关于以集中竞价交易方式回购股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、回购股份的基本信息 公司于 2024 年 2 月 7 日召开第三届董事会第六次会议，审议通过了《关于 以集中竞价交易方式回购股份方案的议案》，同意公司以自有资金或自筹资金通 过上海证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人民币 普通股（A 股）股票，本次回购的股份将用于员工持股计划或股权激励，回购价 格不超过人民币 39.33 元/股（含），回购资金总额不低于人民币 5,000.00 万元 （含），不超过人民币 10,000.00 万元（含），回购期限自公司董事会审议通过本 次回购股份方案之日起 12 个月内。具体内容详见公司于 2024 年 2 月 8 日在上 海证券交易所网站（www.sse.com.cn）披露的《关于以集中竞价交易方式回购股 份方案的公告》（公告编号：2024-006）。 2024 年 4 ...

一、回购股份的基本信息 证券代码：688298 证券简称：东方生物 公告编号：2024-035 浙江东方基因生物制品股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 回购方案首次披露日 | 2024 年 2 月 8 日，由实际控制人方剑秋先生、 方炳良先生、方效良先生提议 | | --- | --- | | 回购方案实施期限 | 2024 年 2 月 7 日—2025 年 2 月 6 日 | | 预计回购金额 | 25,000 万元—30,000 万元人民币 | | 回购用途 | □减少注册资本 | | | ☑用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 40.33 万股 | | 累计已回购股份数占股本比例 | 0.20% | | 累计已回购金额 | 1,278.07 万元 | | 实际回购价格区间 | 31.31 元/股—31.90 元/股 | 重要内容提示： 2024 年 5 ...

Market Overview - In 2023, the global IVD market size was $106.26 billion, a decrease of 16.59% year-on-year, with non-COVID IVD at $98.59 billion, growing by 4%[6]. - The global IVD market is projected to reach approximately $110.3 billion in 2024, with a compound annual growth rate of about 3.8%[11]. - The IVD market in China was valued at approximately 125.3 billion yuan in 2023, with an expected growth to 133.2 billion yuan in 2024, reflecting a compound annual growth rate of about 6.3%[11]. - The global IVD market size reached $106.26 billion in 2023, with an expected growth to $128 billion by 2028, reflecting a compound annual growth rate (CAGR) of approximately 3.8%[68]. - The Chinese IVD market is projected to reach approximately 219.8 billion CNY by 2025, with a compound annual growth rate (CAGR) of 15.38% from 2020 to 2025[195]. - In 2023, the Chinese IVD market size is reported to be 125.3 billion CNY, with the immunodiagnostics segment holding the largest market share at 35%[199]. Company Performance - The company's revenue and net profit for 2023 are expected to decline significantly compared to 2022 due to the removal of COVID testing product sales from the performance base[7]. - The company's net profit attributable to shareholders for the year 2023 was -397,583,595.27 RMB[21]. - The company reported a significant increase in revenue, achieving a total of RMB 1.2 billion for the fiscal year 2023, representing a growth of 25% compared to the previous year[31]. - The company's operating revenue for 2023 was approximately ¥820.16 million, a significant decrease of 90.65% compared to ¥8.77 billion in the previous year[39]. - The net profit for 2023 was a loss of approximately ¥418.27 million, marking a decline of 119.94% from a profit of ¥2.10 billion in 2022[158]. - The company reported a net cash outflow from operating activities of approximately ¥1.65 billion, a decline of 154.93% compared to the previous year[158]. Strategic Goals and Future Outlook - The company aims for a certain growth in overall operating performance in 2024, focusing on routine testing business and expanding market share[12]. - The company plans to enhance its strategic layout and improve operational efficiency through resource integration and centralized management in 2024[12]. - The company will prioritize cost reduction strategies, optimizing production costs and management expenses in 2024[14]. - The company has set a revenue guidance for 2024, projecting an increase of 20% to reach RMB 1.44 billion[31]. - The company anticipates a recovery in IVD business in 2024 following a temporary downturn in 2023 due to regulatory impacts[194]. - The company expects a revenue growth of 20% year-over-year for the upcoming fiscal year, driven by new product launches and market expansion[116]. Research and Development - The company intends to increase R&D investment to enhance product lines and address registration certificate shortcomings in 2024[15]. - Research and development efforts have increased by 15%, focusing on molecular diagnostics and point-of-care testing technologies[31]. - The company invested a total of 261 million RMB in R&D in 2023, resulting in 169 new authorized patents and software copyrights, with a cumulative total of 771 authorized patents and copyrights by the end of the year[57][58]. - Total R&D expenditure for the year was ¥260,861,479.83, a decrease of 49.01% compared to ¥511,564,379.22 in the previous year[128]. - The significant reduction in R&D investment was primarily due to a decrease in related expenditures for COVID-19 testing product development[129]. Product Development and Innovation - New product launches include a COVID-19 antibody testing kit, which has received CE certification, allowing entry into the European market[29]. - The company has expanded its product line to include animal/pet vaccines and testing, enhancing its overall industry chain layout[55]. - The company has introduced new animal vaccine products during the reporting period, expanding its product offerings[61]. - The introduction of a new diagnostic kit is anticipated to capture a 5% market share within the first year of launch[62]. - The company launched multiple new diagnostic products, including the "Healgen® Accurate Oral Fluid Drug Test" and "COVID-19/Flu A&B Ag Combo Rapid Test Cassette" with FDA and MHRA approvals[112][113]. - The company launched multiple quantitative test kits, including BNP, D-Dimer, and Myo, all receiving EU CE certification on September 13, 2023[124]. Market Expansion and Strategic Partnerships - The company is actively pursuing market expansion, with plans to enter Southeast Asian markets by mid-2024[31]. - The company is exploring strategic partnerships to enhance its distribution network and improve supply chain efficiency[31]. - The company has established strategic partnerships with major clients such as McKesson, Walmart, and Roche, enhancing its market channel advantages[139]. - The company is focusing on expanding its market presence in Europe with the recent CE certifications for its diagnostic products[120]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[114]. Financial Management and Cost Control - The company will reduce acquisition activities in the short term while focusing on improving the operational efficiency of existing subsidiaries and acquired projects[16]. - The company has implemented cost-control measures that have reduced operational expenses by 10% year-over-year[31]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[23]. - The company plans not to distribute profits for the year 2023, with no cash dividends or stock bonuses proposed[21]. - The company faced substantial management expenses of ¥372.36 million, an increase of 37.56% year-on-year, primarily due to increased depreciation and amortization[158]. Risks and Challenges - The report includes a risk statement regarding forward-looking statements, indicating that future strategies and plans do not constitute a commitment to investors[22]. - The company is at risk of continued losses in 2024 due to high costs associated with strategic goals, including market expansion and project acquisitions[143]. - The company is heavily reliant on a few major clients, which poses a risk to future operational performance if stable partnerships are not established[146]. - The company's revenue from overseas sales remains high, exposing it to risks from geopolitical and trade policy changes[146].

证券代码：688298 证券简称：东方生物 公告编号：2024-032 浙江东方基因生物制品股份有限公司 关于召开 2023 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 05 月 14 日(星期二)上午 10:00-11:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.s seinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 05 月 07 日(星期二)至 05 月 13 日(星期一)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zqb@orientgen e.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 （三）会议召开方式：上证路演中心网络互动 三、参加人员 董事长：方剑秋 总经理：方效良 董事会秘书、副总经理：章叶平 财务总监、副总经理：俞锦洪 浙江东方基因生物制品股份有限公司（以下简称"公司"）已于 2024 年 4 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥182,922,481.69, representing a decrease of 51.36% compared to the same period last year[5] - The net profit attributable to shareholders was -¥67,353,495.40, a decline of 33.82% year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥109,011,042.72, reflecting a significant decrease of 281.26%[5] - The net cash flow from operating activities was -¥211,864,976.91, an increase in outflow of 71.04% compared to the previous year[5] - The company's main business revenue for Q1 2024 was RMB 183 million, a significant decline from RMB 372 million in the same period last year, primarily due to higher management and R&D expenses[13] - Net loss for Q1 2024 was ¥69,955,283.74, compared to a net loss of ¥46,412,877.00 in Q1 2023, representing an increase in loss of 50.9%[20] - The company reported a gross profit margin of -47.0% in Q1 2024, compared to -38.9% in Q1 2023[20] Research and Development - Research and development expenses totaled ¥71,964,517.95, an increase of 38.65% year-over-year[5] - The proportion of R&D expenses to operating revenue was 39.34%, up by 25.54 percentage points from the previous year[6] - Research and development expenses for Q1 2024 were ¥71,964,517.95, an increase of 38.7% compared to ¥51,904,828.32 in Q1 2023[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,759,354,189.43, a decrease of 2.63% from the end of the previous year[6] - The company's total assets amounted to ¥8,759,354,189.43, a decrease from ¥8,995,951,150.74 in the previous year[18] - Total liabilities decreased to ¥1,222,534,023.61 from ¥1,446,223,002.71, reflecting a reduction of 15.5%[18] - As of March 31, 2024, the total current assets amounted to RMB 5.27 billion, down from RMB 5.90 billion at the end of 2023[16] - The total long-term investments decreased slightly to RMB 20.37 million from RMB 21.24 million[16] Shareholder Information - The company had a total of 16,045 common shareholders at the end of the reporting period[10] - The top three shareholders collectively hold 48.56% of the company, with Anji Fulanglai Import and Export Trade Co., Ltd. owning 19.50%[12] Cash Flow and Financing Activities - In Q1 2024, the company reported cash inflows from operating activities of CNY 228,718,943.11, a slight decrease from CNY 235,205,118.36 in Q1 2023[23] - The net cash outflow from operating activities was CNY -211,864,976.91, improving from CNY -731,563,866.64 in the same period last year[23] - Investment activities generated a net cash outflow of CNY -100,731,912.72, compared to CNY -56,819,148.88 in Q1 2023[23] - The company received CNY 532,446,296.68 from investment recoveries, significantly higher than CNY 211,000,000.00 in the previous year[23] - Cash and cash equivalents at the end of Q1 2024 totaled CNY 2,595,292,577.44, down from CNY 6,229,181,276.83 at the end of Q1 2023[24] - The company reported cash inflows from financing activities of CNY 105,960,000.00, a decrease from CNY 500,000,000.00 in Q1 2023[24] - The net cash outflow from financing activities was CNY -30,026,504.17, compared to a net inflow of CNY 498,216,180.60 in the same quarter last year[24] Other Information - The company has not disclosed any significant new product developments or market expansion strategies in the current report[13] - The company has not participated in any financing or margin trading activities during the reporting period[12] - The company experienced a foreign exchange impact of CNY 9,312,629.07 on cash and cash equivalents[24] - The company paid CNY 20,847,373.53 in taxes during Q1 2024, down from CNY 103,378,871.24 in the previous year[23]